Dems fire off a silly pricing bill; What's wrong with Novartis?
Endpoints assesses the big biopharma stories of the week, with a little added commentary on what they mean for the industry.
The Democrats field …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.